Patents by Inventor James A. Burke

James A. Burke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5326763
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a reduction inflammation in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: July 5, 1994
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler
  • Patent number: 5281591
    Abstract: Methods and pharmaceutical formulations of alpha.sub.2 agonists and alpha.sub.3 antagonists which are useful in lowering intraocular pressure (IOP) and treatment of intraocular hypertension. Co-administration of a therapeutic amount of alpha.sub.2 agonist with a potentiating amount of alpha.sub.3 agonist is effective in lowering IOP and treatment of intraocular hypertension.
    Type: Grant
    Filed: October 28, 1992
    Date of Patent: January 25, 1994
    Assignee: Allergan, Inc.
    Inventor: James A. Burke
  • Patent number: 5231096
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## ,pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: July 27, 1993
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler
  • Patent number: 5215991
    Abstract: Methods and pharmaceutical compositions of alpha.sub.2 agonists and Na.sup.+ /H.sup.+ exchange inhibitors which are useful in lowering intraocular pressure (IOP) and treatment of intraocular hypertension are disclosed. Co-administration of a therapeutic amount of alpha.sub.2 agonist with a potentiating amount of Na.sup.+ /H.sup.+ exchange inhibitor is effective in lowering IOP and treatment of intraocular hypertension.
    Type: Grant
    Filed: December 20, 1990
    Date of Patent: June 1, 1993
    Assignee: Allergan, Inc.
    Inventor: James A. Burke
  • Patent number: 5180721
    Abstract: Methods and pharmaceutical formulations of alpha.sub.2 agonists and alpha.sub.3 antagonists which are useful in lowering intraocular pressure (IOP) and treatment of intraocular hypertension. Co-administration of a therapeutic amount of alpha.sub.2 agonist with a potentiating amount of alpha.sub.3 agonist is effective in lowering IOP and treatment of intraocular hypertension.
    Type: Grant
    Filed: May 30, 1991
    Date of Patent: January 19, 1993
    Assignee: Allergan, Inc.
    Inventor: James A. Burke
  • Patent number: 5021410
    Abstract: Methods and pharmaceutical formulations of alpha.sub.2 agonists and alpha.sub.3 antagonists which are useful in lowering intraocular pressure (IOP) and treatment of intraocular hypertension. Co-administration of a therapeutic amount of alpha.sub.2 agonist with a potentiating amount of alpha.sub.3 agonist is effective in lowering IOP and treatment of intraocular hypertension.
    Type: Grant
    Filed: May 22, 1989
    Date of Patent: June 4, 1991
    Assignee: Allergan, Inc.
    Inventor: James A. Burke
  • Patent number: 4699267
    Abstract: A luggage case provided with a removably mounted shoe rack for storing and transporting a plurality of pairs of shoes. The generally conventional luggage case includes a rectangular compartment and a hinged cover detachably connected thereto to open and close the compartment. The shoe rack includes rectangular, open rigid frame which is conformed to closely fit within the confines of the luggage compartment and a pair of horizontally extending rows of shoe-receiving members supported on said frame. The shoe receiving members are in the form of inwardly and upwardly directed prongs adapted to receive a shoe, toe first, with the general boundaries of said frame. Also included is a flexible pocket formed in the top of the frame having a closure flap to permit storage of other personal items therein.
    Type: Grant
    Filed: November 28, 1986
    Date of Patent: October 13, 1987
    Inventor: James A. Burke